Day: October 17, 2022

Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster

NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry

error: Content is protected !!